Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Pemafibrate24 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00165 | 35203610 | Biomedicines | Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study. | 2022 | Details |
| A00877 | 34943553 | Diagnostics (Basel) | Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. | 2021 | Details |
| A01773 | 34622006 | JGH Open | Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. | 2021 | Details |
| A02022 | 34528723 | Aliment Pharmacol Ther | Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A02657 | 34295984 | Clin Exp Hepatol | Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. | 2021 | Details |
| A03683 | 33903148 | Gut | Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. | 2021 | Details |
| A04448 | 33612679 | Intern Med | Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. | 2021 | Details |
| A05052 | 33392801 | Curr Atheroscler Rep | Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel? | 2021 | Details |
| A05449 | 33253343 | Yonago Acta Med | Erratum for Ikeda et al., "Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease". | 2020 | Details |
| A05710 | 33145434 | Clin Exp Hepatol | Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A06330 | 32926754 | Hepatol Res | Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. | 2020 | Details |
| A06427 | 32884438 | Yonago Acta Med | Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | 2020 | Details |
| A07703 | 32385406 | Sci Rep | Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. | 2020 | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A09774 | 31614690 | Int J Mol Sci | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. | 2019 | Details |
| A13975 | 29662003 | Int J Mol Sci | PPAR Agonists and Metabolic Syndrome: An Established Role? | 2018 | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | 2017 | Details |
| A16762 | 28195199 | Sci Rep | Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. | 2017 | Details |
| A28641 | 35203369 | Cells | Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A28644 | 35194060 | Sci Rep | Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. | 2022 | Details |
| A28693 | 35121372 | Biochem Biophys Res Commun | Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. | 2022 | Details |
| A50017 | 35563117 | Int J Mol Sci | Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate. | 2022 | Details |
| A51813 | 33947390 | Cardiovasc Diabetol | Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. | 2021 | Details |